The US cancer society has lowered the recommended age for bowl cancer screening from 50 to 45. This could benefit RHY in the future with their US GTM strategy.
https://unauthorised investment adv...s-as-us-experts-call-for-younger-testing/amp/
A good summary of the RHY opportunity I found on Twitter "One thing $RHY has going for it is that it has a very low market cap ($19 million, $11m EV), compared to $9,6 billion for Exact Sciences, maker of a faecal colon cancer test. Therefore, if performance is maintained in larger prospective trials, the potential is very material"
on the way to $1, page-17
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RHY (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.7¢ |
Change
-0.033(25.4%) |
Mkt cap ! $15.41M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 12.0¢ | 9.7¢ | $114.8K | 1.082M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5500 | 9.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 164688 | 2 |
View Market Depth
| Last trade - 16.10pm 25/11/2024 (20 minute delay) ? |
| RHY (ASX) Chart |
